Avingtrans medical imaging technology associate firm Adaptix has received US Food and Drug Administration (FDA) 510(k) clearance for its orthopaedic medical imaging product.

The Digital Tomosynthesis Orthopaedic imaging system, which is the first Adaptix medical product, is a portable and low-dose imaging system.

The system is designed to deliver fast X-ray imaging at the point of patient care.

Adaptix has specifically developed the system to provide 3D X-ray imaging of hands, elbows and feet at a fraction of the radiation dose and per-study price of traditional CT systems.

With fewer acquisitions, accelerated patient workflow and improved diagnostic accuracy, the system offers clinicians clearer images than 2D X-ray systems.

Adaptix CEO Mark Evans said: “We are delighted to receive the 510(k) clearance, which allows this innovative technology, and our first medical product, to be marketed in the world’s largest healthcare market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The team are energised by achieving this milestone, and we look forward to delivering enhanced orthopaedic DT imaging systems; a dental DT imaging system; and a chest DT imaging system for Intensive Care and Emergency Department use.

“We see a future where 3D travels to the patient at the point-of-care throughout hospitals, clinics and primary care transforming patient pathways, improving patient experience and reducing the cost of care delivery.”

In 2021, Avingtrans invested £4m to purchase an 11.9% interest in Adaptix. Last December, the company invested a further £2m through a convertible loan.

Adaptix is already offering services to customers in the veterinary and industrial markets.